The Trump administration is presenting the GENEROUS Medicaid drug-pricing model as a nationwide victory. On September 18, the Centers for Medicare & Medicaid Services said all 50 states, the District of Columbia and Puerto Rico had applied to participate, with the administration estimating $64.3 billion in savings over 10 years.
But for Medicaid patients, the announcement is not yet a change they can see at the pharmacy counter. The important details— which medicines will be included, what coverage rules will apply and whether states will actually complete the agreements—are still being worked out.
That distinction matters because Medicaid beneficiaries generally already face limited prescription-drug cost sharing. Federal rules restrict most copayments to nominal amounts, and many beneficiaries are exempt altogether. The direct consumer benefit of a lower government payment may therefore be small unless the savings produce broader coverage, fewer authorization barriers or more dependable access to treatment. KFF’s overview of Medicaid prescription drugs explains how rebates, formularies and utilization controls shape what patients actually experience.
An application is not the same as a finished deal
CMS says 40 states and Puerto Rico had already signed agreements by September 18, while the remaining states have until September 30, 2026, to sign. The agency says the model launched in January 2026 and will run for five years. Under the program, participating manufacturers would provide supplemental rebates intended to bring Medicaid’s net price for selected outpatient drugs closer to prices in certain other countries. CMS’s announcement describes the program as a way to lower spending while improving access.
Reporting by STAT, however, found that officials in several states still viewed participation as undecided or subject to further evaluation. Some states reportedly applied or signed preliminary agreements to obtain pricing information without committing to enter manufacturer-specific rebate agreements.
That is not a minor technicality. A state may want to know whether the federal offer is better than the supplemental rebates it already receives before changing its pharmacy program. The political message—every state is interested—is ahead of the patient-facing answer: which states will use which prices for which drugs under which conditions?
Lower spending does not automatically mean better access
The model is voluntary for manufacturers as well as states. Drug companies choose which products from their portfolios to offer, and CMS negotiates coverage criteria for participating medicines. States that join must use the standardized criteria for selected products rather than independently negotiating separate supplemental rebates for those same drugs.
That could reduce administrative variation. It could also limit the flexibility states currently use to bargain over coverage and utilization. Patients may encounter the policy through a preferred-drug list, a prior-authorization request, a step-therapy requirement, a reauthorization deadline or a switch to another medicine—not through a lower bill.
Those rules are not peripheral to health care. A patient with cancer, diabetes, asthma, HIV, hepatitis, cardiovascular disease or a neurological condition may be able to afford a nominal copayment and still face a serious access problem if a prescription is delayed, denied or changed. For someone whose condition is stable only because a particular medicine is working, continuity can matter more than the government’s accounting price.
KFF’s analysis notes that Medicaid already receives substantial rebates. Across fiscal years 2019 through 2024, statutory and supplemental rebates reduced gross Medicaid prescription-drug spending by an average of 53 percent, according to the analysis. The relevant question is therefore not simply whether a foreign list price is lower than a U.S. list price. It is whether the GENEROUS rebate produces a lower net price than Medicaid is already paying after existing discounts.
The savings estimate is a projection, not a patient result
The administration’s $64.3 billion estimate may prove useful, but it cannot yet be treated as a realized saving. The outcome will depend on manufacturer participation, the drugs selected, the international prices used for comparison and the rebates states already receive.
An Urban Institute analysis estimated that most-favored-nation pricing could generate $8.6 billion in annual Medicaid savings for a group of high-spending brand-name drugs, while also finding that the effect would vary sharply by state. That is a scenario based on specified drugs and assumptions, not a forecast of the final GENEROUS agreements.
KFF similarly cautions that the program’s impact remains uncertain because many of the relevant terms are confidential or not yet available. Existing rebates are already large for some medicines, while a smaller number of high-cost drugs account for a substantial share of Medicaid spending. The model could produce meaningful savings if it reaches heavily used drugs that do not already carry large rebates. It could have a smaller effect if manufacturers select products with limited Medicaid use or if states already have better arrangements.
What patients should watch
The first useful test of the program will not be the size of the administration’s national projection. It will be the publication of specific drug and manufacturer agreements.
- Which medicines are included?
- What prior-authorization and step-therapy rules apply?
- Can patients remain on an effective treatment when a state or managed-care plan changes its preferred list?
- How quickly will exceptions and appeals be handled?
- Will savings support coverage, provider payments or other Medicaid services?
- Will pharmacies and doctors receive clear instructions before the rules change?
- Will CMS measure treatment delays, prescription abandonment and switches between medicines?
Those questions are particularly important for families managing prescriptions for children with chronic conditions, people with disabilities, older adults who qualify for Medicaid and patients whose treatment depends on specialty pharmacies or regular reauthorization.
There is a legitimate case for seeking better prices. Medicaid budgets face pressure, and money saved on medicines could support other services. But a lower government payment is not automatically improved health care. The program should be judged by whether patients obtain necessary medicines more reliably, not only by whether federal and state ledgers show a smaller number.
By September 30, the states may have completed another step in the process. The harder work will follow: identifying the medicines, publishing the conditions and demonstrating that the savings reach patients as better access rather than simply becoming another invisible budget adjustment.
